{"id":1103,"date":"2024-06-05T12:04:49","date_gmt":"2024-06-05T12:04:49","guid":{"rendered":"https:\/\/retirednurseblog.com\/index.php\/2024\/06\/05\/fda-approves-modernas-mrna-rsv-vaccine-for-older-adults\/"},"modified":"2024-06-05T12:04:49","modified_gmt":"2024-06-05T12:04:49","slug":"fda-approves-modernas-mrna-rsv-vaccine-for-older-adults","status":"publish","type":"post","link":"https:\/\/retirednurseblog.com\/index.php\/2024\/06\/05\/fda-approves-modernas-mrna-rsv-vaccine-for-older-adults\/","title":{"rendered":"FDA approves Moderna\u2019s mRNA RSV vaccine for older adults"},"content":{"rendered":"

The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name of mResvia, could be another tool in the country\u2019s RSV arsenal in the fall. <\/p>\n

Moderna\u2019s shot is the third RSV vaccine for people 60 and older that\u2019s gotten the green light from the FDA and the first mRNA vaccine among them. <\/strong>It\u2019s the company\u2019s second product to receive FDA approval, behind its Covid-19 vaccine. <\/p>\n

The other FDA-approved RSV vaccines are made by GSK and Pfizer. There\u2019s also an RSV vaccine for pregnant people in the US that can protect an infant after birth and a preventive antibody that can be given to prevent serious illness in babies. <\/p>\n

The virus is ubiquitous and typically causes mild infection. Globally, about 64 million people get sick with RSV each year, according to the National Institute of Allergy and Infectious Diseases. <\/p>\n

Many people who get RSV feel like they have a cold, and they will typically recover in a few weeks, but the virus can be particularly dangerous for older people, young children and people with underlying health conditions. Depending on how bad the season is, between 60,000 and 160,000 older adults are hospitalized with RSV every year, and between 6,000 and 10,000 die, according to the US Centers for Disease Control and Prevention. <\/p>\n

RSV symptoms can include a runny nose, cough, fever, sneezing, wheezing and a decreased appetite, but an infection can also turn into pneumonia or make underlying breathing problems like asthma or COPD worse. <\/p>\n

In a single year, millions of people are sent to the hospital with a lower respiratory tract infection that started with RSV. Seniors who have underlying heart problems or lung diseases and those with suppressed immune systems are at the highest risk that RSV could turn into pneumonia or kill them. <\/p>\n

Moderna said Friday that approval of its RSV vaccine was based on clinical trial data showing that even about four months after someone gets the shot, the vaccine had an 83.7% efficacy at preventing lower respiratory tract disease. The vaccine trials involved 37,000 adults in 22 countries. <\/p>\n

Moderna says a longer-term analysis showed that the vaccine provided continued protection nearly nine months after vaccination. The company said there were no serious safety concerns identified in the trial, and the most common problems were pain at the injection site, headache and fatigue. <\/p>\n

\n